Results 251 to 260 of about 478,399 (303)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Treatment Options in Gastroenterology, 2004
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie D, Straley, Norah A, Terrault
openaire +2 more sources
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie D, Straley, Norah A, Terrault
openaire +2 more sources
Clinics in Liver Disease, 2012
The management of chronic hepatitis B virus (HBV) infection requires understanding the natural history of the disease as well as the risks, benefits, and limitations of the therapeutic options. This article covers the principles governing when to start antiviral therapy, discusses recent advances using hepatitis B surface antigen quantification to ...
Alexander, Kuo, Robert, Gish
openaire +2 more sources
The management of chronic hepatitis B virus (HBV) infection requires understanding the natural history of the disease as well as the risks, benefits, and limitations of the therapeutic options. This article covers the principles governing when to start antiviral therapy, discusses recent advances using hepatitis B surface antigen quantification to ...
Alexander, Kuo, Robert, Gish
openaire +2 more sources
Interferon in chronic hepatitis B
Antiviral Research, 1994In patients with typical chronic hepatitis B (HBsAg, HBeAg, HBV-DNA-positive), treatment with interferon-alpha must be carried out for 4-6 months on an alternate-day basis and dosage should be not less than 5 million units/square meter of body surface.
SARACCO, Giorgio Maria +2 more
openaire +3 more sources
Annals of Internal Medicine, 1988
Excerpt To the Editor:Perrillo and colleagues (1) make an important contribution to the study of chronic hepatitis B treatment.
openaire +2 more sources
Excerpt To the Editor:Perrillo and colleagues (1) make an important contribution to the study of chronic hepatitis B treatment.
openaire +2 more sources
Progress in liver diseases, 1990
Chronic hepatitis B is said to affect at least 5 percent of the world's population and to be the chief cause of cirrhosis and hepatocellular carcinoma.1 The World Health Organization lists hepatiti...
S W, Schalm +2 more
openaire +3 more sources
Chronic hepatitis B is said to affect at least 5 percent of the world's population and to be the chief cause of cirrhosis and hepatocellular carcinoma.1 The World Health Organization lists hepatiti...
S W, Schalm +2 more
openaire +3 more sources
2016
A 45-year-old male Chinese university lecturer presented to his GP with malaise and dark urine. He was referred to the local infectious diseases clinic, and blood tests were as follows:
Navjyot Hansi +2 more
openaire +3 more sources
A 45-year-old male Chinese university lecturer presented to his GP with malaise and dark urine. He was referred to the local infectious diseases clinic, and blood tests were as follows:
Navjyot Hansi +2 more
openaire +3 more sources
BMJ, 2009
Clinical course and treatment of this infection common in Asia and the challenge of its global ...
Arthur C K Wong, Ching Lung Lai
openaire +1 more source
Clinical course and treatment of this infection common in Asia and the challenge of its global ...
Arthur C K Wong, Ching Lung Lai
openaire +1 more source
Treatment of chronic hepatitis B
Nature Clinical Practice Gastroenterology & Hepatology, 2006Treatment of chronic hepatitis B has improved substantially over the past five years. Pegylated interferon alpha2a and entecavir have been approved by the FDA and joined the armamentarium of therapies that includes inteferon alpha (IFN-alpha), lamivudine, and adefovir dipivoxil. Several key questions come to mind regarding treatment. Who should receive
Smruti R, Mohanty +2 more
openaire +2 more sources